Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 4 boards, counting each seat separately. Longest: Neurogene Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
MapLight Therapeutics Inc. June 23, 202689.8%
-
Prelude Therapeutics Incorporated June 11, 202596.0%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 23, 2026 | MapLight Therapeutics Inc. | Grant or award | +7,864 | — | — |
| Apr 1, 2025 | Alumis Inc. | Open-market purchase | +15,650 | $6.44 | $100,786 |
| Jul 1, 2024 | Alumis Inc. | Sold back to the company | −90,804 | — | — |
| Jul 1, 2024 | Alumis Inc. | Grant or award | +90,804 | — | — |
Questions about Martin Babler
What boards is Martin Babler on?
Martin Babler sits on the boards of Alumis Inc., MapLight Therapeutics Inc., Neurogene Inc. and Prelude Therapeutics Incorporated.
What company is Martin Babler the CEO of?
Martin Babler has been President, CEO and Chairman of Alumis Inc. since June 2024.
How long has Martin Babler served on boards?
Our records show at least 10 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.